: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

The Angels Initiative

Stroke prevention

Nuclear Medicine

Free Subscription

Articles published in J Nucl Med
Retrieve available abstracts of 389 articles:
HTML format

Single Articles

September 2022

DERLIN T, Spencer BA, Mamach M, Abdelhafez Y, et al
Exploring Vessel Wall Biology In Vivo By Ultra-Sensitive Total-Body Positron Emission Tomography.
J Nucl Med. 2022 Sep 29. pii: jnumed.122.264550. doi: 10.2967/jnumed.122.264550.
PubMed Abstract available

SEIBYL JP, DuBois JM, Racine A, Collins J, et al
A Visual Interpretation Algorithm for Assessing Brain Tauopathy with 18-F MK-6240 Positron Emission Tomography.
J Nucl Med. 2022 Sep 29. pii: jnumed.122.264371. doi: 10.2967/jnumed.122.264371.
PubMed Abstract available

SMITH AM, Obuchowski NA, Foster NL, Klein G, et al
The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification.
J Nucl Med. 2022 Sep 22. pii: jnumed.122.264031. doi: 10.2967/jnumed.122.264031.
PubMed Abstract available

SHANBHAG AD, Miller RJH, Pieszko K, Lemley M, et al
Deep Learning-based Attenuation Correction Improves Diagnostic Accuracy of Cardiac SPECT.
J Nucl Med. 2022 Sep 22. pii: jnumed.122.264429. doi: 10.2967/jnumed.122.264429.
PubMed Abstract available

MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
PubMed Abstract available

PUUVUORI E, Chiodaroli E, Estrada S, Cheung P, et al
PET imaging of neutrophil elastase with (11)C-GW457427 in Acute Respiratory Distress Syndrome in pigs.
J Nucl Med. 2022 Sep 15. pii: jnumed.122.264306. doi: 10.2967/jnumed.122.264306.
PubMed Abstract available

TRAUTWEIN NF, Reischl G, Seitz C, Dittmann H, et al
First in human PET/MRI imaging of in vivo GD2 expression in osteosarcoma.
J Nucl Med. 2022 Sep 15. pii: jnumed.122.264626. doi: 10.2967/jnumed.122.264626.
PubMed

BAILLY M, Thibault F, Metrard G, Courtehoux M, et al
Precision of Myocardial Blood Flow and Flow Reserve measurement during CZT-SPECT perfusion imaging processing: intra- and inter-observer variability.
J Nucl Med. 2022 Sep 15. pii: jnumed.122.264454. doi: 10.2967/jnumed.122.264454.
PubMed Abstract available

August 2022

LAFOREST R, Ghai A, Fraum TJ, Oyama R, et al
First-in-Human Evaluation of Safety and Dosimetry of (64)Cu-LLP2A for PET Imaging.
J Nucl Med. 2022 Aug 25. pii: jnumed.122.264349. doi: 10.2967/jnumed.122.264349.
PubMed Abstract available

PATHMANANDAVEL S, Crumbaker M, Ho B, Yam AO, et al
Evaluation of (177)Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective (177)Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
J Nucl Med. 2022 Aug 25. pii: jnumed.122.264398. doi: 10.2967/jnumed.122.264398.
PubMed Abstract available

SILVA-RODRIGUEZ J, Labrador-Espinosa MA, Moscoso A, Scholl M, et al
Differential effects of tau stage, Lewy body pathology, and substantia nigra degeneration on FDG-PET patterns in clinical AD.
J Nucl Med. 2022 Aug 25. pii: jnumed.122.264213. doi: 10.2967/jnumed.122.264213.
PubMed Abstract available

HAGENS MJ, Oprea-Lager DE, Vis AN, Wondergem M, et al
Reproducibility of PSMA PET/CT Imaging for primary staging of treatment-naive prostate cancer patients depends on the applied radiotracer: a retrospective study.
J Nucl Med. 2022 Aug 25. pii: jnumed.121.263139. doi: 10.2967/jnumed.121.263139.
PubMed Abstract available

SHIN J, Parker MFL, Zhu I, Alanizi A, et al
Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
PubMed Abstract available

CARLSEN EA, Loft M, Loft A, Czyzewska D, et al
Prospective phase II trial of [(68)Ga]Ga-NODAGA-E[c(RGDyK)]2 PET/CT imaging of integrin alphavbeta3 for prognostication in patients with neuroendocrine neoplasms.
J Nucl Med. 2022 Aug 18. pii: jnumed.122.264383. doi: 10.2967/jnumed.122.264383.
PubMed Abstract available

KERSTING D, Jentzen W, Jeronim D, Mavroeidi IA, et al
Lesion Quantification Accuracy of Digital (90)Y PET Imaging in the Context of Dosimetry in Systemic FAPI Radionuclide Therapy.
J Nucl Med. 2022 Aug 18. pii: jnumed.122.264338. doi: 10.2967/jnumed.122.264338.
PubMed Abstract available

EVANGELOU P, Omrane MA, Thurow J, Mix M, et al
(68)Ga-DOTA Positron Emission Tomography for Diagnosis of Spinal Cerebrospinal Fluid Leaks.
J Nucl Med. 2022 Aug 18. pii: jnumed.122.264059. doi: 10.2967/jnumed.122.264059.
PubMed Abstract available

Cherry Receives 2022 Benedict Cassen Prize.
J Nucl Med. 2022;63:10N.
PubMed

KMETYUK Y, Czernin J, Herrmann K
Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann.
J Nucl Med. 2022;63:1127-1130.
PubMed

Schwaiger Recognized with de Hevesy Nuclear Pioneer Award.
J Nucl Med. 2022;63:12N.
PubMed

Mach Honored with SNMMI 2022 Paul C. Aebersold Award.
J Nucl Med. 2022;63:13N.
PubMed

JNM Impact Factor Rises Again.
J Nucl Med. 2022;63:18N.
PubMed

Science at the SNMMI Annual Meeting.
J Nucl Med. 2022;63:19N-20N.
PubMed

SNMMI Newsline.
J Nucl Med. 2022;63:9N-20N.
PubMed

PAPPAS V
SNMMI Leadership Update: SNMMI 2022 Annual Meeting-In Person at Last.
J Nucl Med. 2022;63:15N.
PubMed

GONZALEZ-MONTORO A, Ullah MN, Levin CS
Advances in Detector Instrumentation for PET.
J Nucl Med. 2022;63:1138-1144.
PubMed Abstract available

LEE JH, Simeon FG, Liow JS, Morse CL, et al
In Vivo Evaluation of 6 Analogs of (11)C-ER176 as Candidate (18)F-Labeled Radioligands for 18-kDa Translocator Protein.
J Nucl Med. 2022;63:1252-1258.
PubMed Abstract available

BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
J Nucl Med. 2022;63:1259-1265.
PubMed Abstract available

July 2022

LANG M, Spektor AM, Hielscher T, Hoppner J, et al
Static and dynamic (68)Ga-FAPI PET/CT for the detection of malignant transformation of intraductal papillary mucinous neoplasia of the pancreas.
J Nucl Med. 2022 Jul 29. pii: jnumed.122.264361. doi: 10.2967/jnumed.122.264361.
PubMed Abstract available

GUEDJ E, Horowitz T
Brain Metabolic PET Findings on the Long-Term Effects of COVID-19.
J Nucl Med. 2022 Jul 29. pii: jnumed.122.264179. doi: 10.2967/jnumed.122.264179.
PubMed

RUDDY TD, Al-Mallah M, Arrighi JA, Bois JP, et al
SNMMI/ACR/ASNC/SCMR Joint Credentialing Statement for Cardiac PET/MRI.
J Nucl Med. 2022 Jul 19. pii: jnumed.122.264200. doi: 10.2967/jnumed.122.264200.
PubMed

SEIBYL JP
Alpha-synuclein PET and Parkinson's Disease Therapeutic Trials: Ever the Twain Shall Meet?
J Nucl Med. 2022 Jul 19. pii: jnumed.122.263918. doi: 10.2967/jnumed.122.263918.
PubMed Abstract available

GEORGI TW, Stoevesandt D, Kurch L, Bartelt JM, et al
Optimized whole-body positron emission tomography magnetic resonance imaging sequence workflow in pediatric Hodgkin lymphoma patients.
J Nucl Med. 2022 Jul 14. pii: jnumed.122.264112. doi: 10.2967/jnumed.122.264112.
PubMed Abstract available

KOEHLER D, Sauer M, Klutmann S, Apostolova I, et al
Feasibility of (99m)Tc-MIP-1404 for SPECT/CT imaging and subsequent PSMA-radioguided surgery in early biochemical recurrent prostate cancer: a case series of 9 patients.
J Nucl Med. 2022 Jul 14. pii: jnumed.122.263892. doi: 10.2967/jnumed.122.263892.
PubMed Abstract available

KIM MJ, Juarez Anaya F, Manly LS, Lee JH, et al
Whole-body PET imaging in humans shows that (11)C-PS13 is selective for cyclooxygenase-1 and can measure the in vivo potency of nonsteroidal anti-inflammatory drugs.
J Nucl Med. 2022 Jul 7. pii: jnumed.122.264061. doi: 10.2967/jnumed.122.264061.
PubMed Abstract available

ISHII K, Hanaoka K, Watanabe S, Morimoto-Ishikawa D, et al
High-resolution silicon photomultiplier time-of-flight dedicated head PET system for clinical brain studies.
J Nucl Med. 2022 Jul 7. pii: jnumed.122.264080. doi: 10.2967/jnumed.122.264080.
PubMed Abstract available

LI RG, Stenberg VY, Larsen RH
A Novel Experimental Generator for Production of High Purity Lead-212 for Use in Radiopharmaceuticals.
J Nucl Med. 2022 Jul 7. pii: jnumed.122.264009. doi: 10.2967/jnumed.122.264009.
PubMed Abstract available

SNMMI Image of the Year 2022: PET/CT Biomarker Predicts Post-MI Cardiac Remodeling.
J Nucl Med. 2022;63:16N.
PubMed

STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 2: Inflammation, Fibrosis, Thrombosis, Calcification, and Amyloidosis Imaging.
J Nucl Med. 2022;63:986-994.
PubMed Abstract available

New Officers for SNMMI and SNMMI-TS.
J Nucl Med. 2022;63:17N-18N.
PubMed

CZERNIN J, Adams T, Calais J
More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging.
J Nucl Med. 2022;63:969-970.
PubMed

GHESANI M
SNMMI Leadership Update: Opportunities for Growth in Nuclear Medicine and Molecular Imaging.
J Nucl Med. 2022;63:20N.
PubMed

SEGALL G
Recognition of the ABNM by the NRC.
J Nucl Med. 2022;63:19N.
PubMed

SNMMI Newsline.
J Nucl Med. 2022;63:15N-26N.
PubMed

GRKOVSKI M, Modak S, Zanzonico PB, Carrasquillo JA, et al
Biodistribution and Radiation Dosimetry of Intraperitoneally Administered (124)I-Omburtamab in Patients with Desmoplastic Small Round Cell Tumors.
J Nucl Med. 2022;63:1094-1100.
PubMed Abstract available

DRESSING A, Bormann T, Blazhenets G, Schroeter N, et al
Neuropsychologic Profiles and Cerebral Glucose Metabolism in Neurocognitive Long COVID Syndrome.
J Nucl Med. 2022;63:1058-1063.
PubMed Abstract available

June 2022

PARIHAR AS, Mhlanga J, Ronstrom C, Schmidt LR, et al
Diagnostic accuracy of (99m)Tc-Sestamibi SPECT/CT for characterization of solid renal masses.
J Nucl Med. 2022 Jun 30. pii: jnumed.122.264329. doi: 10.2967/jnumed.122.264329.
PubMed Abstract available

SHIYAM SUNDAR LK, Yu J, Muzik O, Kulterer O, et al
Fully-automated, semantic segmentation of whole-body (18)F-FDG PET/CT images based on data-centric artificial intelligence.
J Nucl Med. 2022 Jun 30. pii: jnumed.122.264063. doi: 10.2967/jnumed.122.264063.
PubMed Abstract available

WAKABAYASHI Y, Strenkona P, Arakawa R, Yan X, et al
First-in-human evaluation of (18)F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B.
J Nucl Med. 2022 Jun 30. pii: jnumed.122.263838. doi: 10.2967/jnumed.122.263838.
PubMed Abstract available

ZHOU R, Choi H, Cao J, Pantel A, et al
(18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
PubMed Abstract available

PATHMANANDAVEL S, Crumbaker M, Nguyen A, Yam AOW, et al
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with (177)LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
J Nucl Med. 2022 Jun 23. pii: jnumed.122.264104. doi: 10.2967/jnumed.122.264104.
PubMed Abstract available

LE TM, Lee HR, Abt ER, Rashid K, et al
(18)F-FDG PET visualizes systemic STING agonist-induced lymphocyte activation in preclinical models.
J Nucl Med. 2022 Jun 23. pii: jnumed.122.264121. doi: 10.2967/jnumed.122.264121.
PubMed Abstract available

ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
(89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
PubMed Abstract available

REICHKENDLER M, Andersen FL, Borgwardt L, Nygaard U, et al
Long axial field of view with 5 min acquisition time enables PET/CT in toddler without sedation.
J Nucl Med. 2022 Jun 16. pii: jnumed.121.263626. doi: 10.2967/jnumed.121.263626.
PubMed

NITSCHE C, Mascherbauer K, Calabretta R, Koschutnik M, et al
Prevalence and outcomes of cardiac amyloidosis in all-comer referrals for bone scintigraphy.
J Nucl Med. 2022 Jun 16. pii: jnumed.122.264041. doi: 10.2967/jnumed.122.264041.
PubMed Abstract available

GIRUM KB, Rebaud L, Cottereau AS, Meignan M, et al
(18)F-FDG PET maximum intensity projections and artificial intelligence: a win-win combination to easily measure prognostic biomarkers in DLBCL patients.
J Nucl Med. 2022 Jun 16. pii: jnumed.121.263501. doi: 10.2967/jnumed.121.263501.
PubMed Abstract available

ANTONI G, Lubberink M, Sorensen J, Lindstrom E, et al
In Vivo Visualization and Quantification of Neutrophil Elastase in Lungs of COVID-19 Patients - A First-In-Human Positron Emission Tomography Study with (11)C-GW457427.
J Nucl Med. 2022 Jun 9. pii: jnumed.122.263974. doi: 10.2967/jnumed.122.263974.
PubMed Abstract available

SIEBINGA H, Olde Heuvel J, Rijkhorst EJ, Hendrikx JJMA, et al
The Impact of Peptide Amount on Tumor Uptake to Assess PSMA Receptor Saturation on (68)Ga-PSMA-11 PET/CT in Primary Prostate Cancer Patients.
J Nucl Med. 2022 Jun 9. pii: jnumed.122.264101. doi: 10.2967/jnumed.122.264101.
PubMed Abstract available

POMYKALA KL, Herrmann K, Padhani AR, Hofman MS, et al
Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Prostate Cancer: We have the answers.
J Nucl Med. 2022 Jun 9. pii: jnumed.122.264394. doi: 10.2967/jnumed.122.264394.
PubMed

AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
J Nucl Med. 2022;63:15N-35N.
PubMed

MINOSHIMA S, Cross D, Thientunyakit T, Foster NL, et al
(18)F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies.
J Nucl Med. 2022;63.
PubMed Abstract available

CHAPLEAU M, Iaccarino L, Soleimani-Meigooni D, Rabinovici GD, et al
The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review.
J Nucl Med. 2022;63.
PubMed Abstract available

TIEPOLT S, Meyer PM, Patt M, Deuther-Conrad W, et al
PET Imaging of Cholinergic Neurotransmission in Neurodegenerative Disorders.
J Nucl Med. 2022;63.
PubMed Abstract available

GROOT C, Villeneuve S, Smith R, Hansson O, et al
Tau PET Imaging in Neurodegenerative Disorders.
J Nucl Med. 2022;63.
PubMed Abstract available

KENOU BV, Manly LS, Rubovits SB, Umeozulu SA, et al
Cyclooxygenases as Potential PET Imaging Biomarkers to Explore Neuroinflammation in Dementia.
J Nucl Med. 2022;63.
PubMed Abstract available

SNMMI Newsline.
J Nucl Med. 2022;63:13N-35N.
PubMed

Outstanding JNMT Articles for 2021.
J Nucl Med. 2022;63:13N.
PubMed

WAHL RL
SNMMI Leadership Update: Putting Patients First: A Year in Review.
J Nucl Med. 2022;63:14N.
PubMed

CARSON RE, Naganawa M, Toyonaga T, Koohsari S, et al
Imaging of Synaptic Density in Neurodegenerative Disorders.
J Nucl Med. 2022;63.
PubMed Abstract available

MASDEU JC, Pascual B, Fujita M
Imaging Neuroinflammation in Neurodegenerative Disorders.
J Nucl Med. 2022;63.
PubMed Abstract available

BARTHEL H, Villemagne VL, Drzezga A
Future Directions in Molecular Imaging of Neurodegenerative Disorders.
J Nucl Med. 2022;63.
PubMed Abstract available

VILLEMAGNE VL, Barthel H
Molecular Imaging of Neurodegeneration: The Way to New Horizons.
J Nucl Med. 2022;63.
PubMed

LEE ST, Emmett LM, Pattison DA, Hofman MS, et al
The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective.
J Nucl Med. 2022;63:819-822.
PubMed Abstract available

WU M, Ning J, Li J, Lai Z, et al
Feasibility of In Vivo Imaging of Fibroblast Activation Protein in Human Arterial Walls.
J Nucl Med. 2022;63:948-951.
PubMed Abstract available

BERTOGLIO D, Verhaeghe J, Wyffels L, Miranda A, et al
Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem.
J Nucl Med. 2022;63:942-947.
PubMed Abstract available

COUSINS MM, Devasia TP, Maurino CM, Mikell J, et al
Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After (90)Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.
J Nucl Med. 2022;63:882-889.
PubMed Abstract available

May 2022

GLATTING FM, Hoppner J, Liew DP, van Genabith A, et al
Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions.
J Nucl Med. 2022 May 26. pii: jnumed.122.264069. doi: 10.2967/jnumed.122.264069.
PubMed Abstract available

SARTOR O
Invited Perspective, Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis.
J Nucl Med. 2022 May 26. pii: jnumed.122.264128. doi: 10.2967/jnumed.122.264128.
PubMed

JHA AK, Bradshaw TJ, Buvat I, Hatt M, et al
Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE guidelines).
J Nucl Med. 2022 May 26. pii: jnumed.121.263239. doi: 10.2967/jnumed.121.263239.
PubMed Abstract available

OUVRARD E, De Mestier L, Boursier C, Lachachi B, et al
(18)F-Fluorodihydroxyphenylalanine PET/CT at the Forefront for Initial and/or Pre-surgical Evaluation of Small Intestine Neuroendocrine Tumors.
J Nucl Med. 2022 May 19. pii: jnumed.122.263984. doi: 10.2967/jnumed.122.263984.
PubMed Abstract available

LOFT M, Christensen C, Clausen MM, Carlsen EA, et al
First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using (18)F-labeled Active-Site Inhibited Factor VII ((18)F-ASIS): Potential as Companion Diagnostic.
J Nucl Med. 2022 May 19. pii: jnumed.122.264068. doi: 10.2967/jnumed.122.264068.
PubMed Abstract available

LOVINFOSSE P, Ferreira M, Withofs N, Jadoul A, et al
Distinction of lymphoma from sarcoidosis at FDG PET/CT - evaluation of radiomic-feature guided machine learning versus human reader performance.
J Nucl Med. 2022 May 19. pii: jnumed.121.263598. doi: 10.2967/jnumed.121.263598.
PubMed Abstract available

ABDELHAFEZ Y, Raychaudhuri SP, Mazza D, Sarkar S, et al
Total-Body (18)F-FDG PET/CT in Autoimmune Inflammatory Arthritis at Ultra-Low Dose: Initial Observations.
J Nucl Med. 2022 May 19. pii: jnumed.121.263774. doi: 10.2967/jnumed.121.263774.
PubMed Abstract available

BARTOS LM, Kunte ST, Beumers P, Xiang X, et al
Single cell radiotracer allocation via immunomagentic sorting (scRadiotracing) to disentangle PET signals at cellular resolution.
J Nucl Med. 2022 May 19. pii: jnumed.122.264171. doi: 10.2967/jnumed.122.264171.
PubMed Abstract available

SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
(18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
PubMed Abstract available

DUAN H, Baratto L, Fan RE, Soerensen SJC, et al
Correlation of (68)Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
J Nucl Med. 2022 May 12. pii: jnumed.122.263971. doi: 10.2967/jnumed.122.263971.
PubMed Abstract available

ERBA PA, Natali A, Strauss HW, Mariani G, et al
Brown Adipose Tissue Activity Following Exposure to the Cold and [(18)F]FDG Uptake: from Possible Pitfall in Early PET Scans to Metabolic Biomarker.
J Nucl Med. 2022 May 12. pii: jnumed.122.264188. doi: 10.2967/jnumed.122.264188.
PubMed

VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
(89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
PubMed Abstract available

MORADI F, Duan H, Song H, Davidzon GA, et al
(68)Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
J Nucl Med. 2022 May 5. pii: jnumed.122.263897. doi: 10.2967/jnumed.122.263897.
PubMed Abstract available

HOPE TA, Jadvar H
Updates to Appropriate Use Criteria for PSMA PET.
J Nucl Med. 2022;63:14N.
PubMed

WAHL RL
SNMMI Leadership Update: SNMMI's Role in the Nuclear Medicine Renaissance.
J Nucl Med. 2022;63:16N-17N.
PubMed

SNMMI Newsline.
J Nucl Med. 2022;63:13N-24N.
PubMed

ASNC/SNMMI Radionuclide Authorized User Training Course.
J Nucl Med. 2022;63:15N.
PubMed

STENDAHL JC, Kwan JM, Pucar D, Sadeghi MM, et al
Radiotracers to Address Unmet Clinical Needs in Cardiovascular Imaging, Part 1: Technical Considerations and Perfusion and Neuronal Imaging.
J Nucl Med. 2022;63:649-658.
PubMed Abstract available

SALAS JR, Clark PM
Signaling Pathways That Drive (18)F-FDG Accumulation in Cancer.
J Nucl Med. 2022;63:659-663.
PubMed Abstract available

TAMBORINO G, Perrot Y, De Saint-Hubert M, Struelens L, et al
Modeling Early Radiation DNA Damage Occurring During (177)Lu-DOTATATE Radionuclide Therapy.
J Nucl Med. 2022;63:761-769.
PubMed Abstract available

ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
Glucagonlike Peptide-1 Receptor Imaging in Individuals with Type 2 Diabetes.
J Nucl Med. 2022;63:794-800.
PubMed Abstract available

HANSCHEID H, Schirbel A, Hartrampf P, Kraus S, et al
Biokinetics and Dosimetry of (177)Lu-Pentixather.
J Nucl Med. 2022;63:754-760.
PubMed Abstract available

FERDINANDUS J, Costa PF, Kessler L, Weber M, et al
Initial Clinical Experience with (90)Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients.
J Nucl Med. 2022;63:727-734.
PubMed Abstract available

April 2022

BROOKS AL, Winton W, Stauff J, Arteaga J, et al
Development of Flourinated NP-59: A Revival of Cholesterol Utilization Imaging with PET.
J Nucl Med. 2022 Apr 28. pii: jnumed.122.263864. doi: 10.2967/jnumed.122.263864.
PubMed Abstract available

DENIS CES, Cousin FC, De Laere B, Hustinx R, et al
Using, (68)Ga-PSMA-11 PET/CT for therapy response assessment in patients with metastatic castration-resistant prostate cancer: an application of EAU/EANM recommendations in clinical practice.
J Nucl Med. 2022 Apr 21. pii: jnumed.121.263611. doi: 10.2967/jnumed.121.263611.
PubMed Abstract available

CHERK MH, Khor R, Barber TW, Yap KSK, et al
Non-Invasive Assessment of Acute Graft vs. Host Disease of the Gastrointestinal Tract Following Allogeneic Haemopoietic Stem Cell Transplantation Using (18)F-FDG PET.
J Nucl Med. 2022 Apr 21. pii: jnumed.121.263688. doi: 10.2967/jnumed.121.263688.
PubMed Abstract available

PIRASTEH A, Periyasamy S, Meudt JJ, Lui Y, et al
Staging Liver Fibrosis by Fibroblast Activation Protein Inhibitor Positron Emission Tomography in a Human-sized Swine Model.
J Nucl Med. 2022 Apr 21. pii: jnumed.121.263736. doi: 10.2967/jnumed.121.263736.
PubMed Abstract available

BROER LN, Knapen DG, Suurs FV, Moen I, et al
(89)Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted (227)Th-conjugate therapy in mice.
J Nucl Med. 2022 Apr 14. pii: jnumed.121.263079. doi: 10.2967/jnumed.121.263079.
PubMed Abstract available

ROTH KS, Voltin CA, van-Heek L, Wegen S, et al
Dual-tracer PET/CT protocol with [(18)F]-FDG and [(68)Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
J Nucl Med. 2022 Apr 14. pii: jnumed.122.263835. doi: 10.2967/jnumed.122.263835.
PubMed Abstract available

DEWARAJA YK, Mirando DM, Peterson A, Niedbala J, et al
A pipeline for automated voxel dosimetry: application in patients with multi-SPECT/CT imaging following (177)Lu peptide receptor radionuclide therapy.
J Nucl Med. 2022 Apr 14. pii: jnumed.121.263738. doi: 10.2967/jnumed.121.263738.
PubMed Abstract available

MESSERSCHMIDT K, Barthel H, Brendel M, Scherlach C, et al
(18)F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy.
J Nucl Med. 2022 Apr 14. pii: jnumed.121.262854. doi: 10.2967/jnumed.121.262854.
PubMed Abstract available

ROSEN J, Ceccon G, Bauer EK, Werner JM, et al
Cost-effectiveness of (18)F-FET PET for early treatment response assessment in glioma patients following adjuvant temozolomide chemotherapy.
J Nucl Med. 2022 Apr 14. pii: jnumed.122.263790. doi: 10.2967/jnumed.122.263790.
PubMed Abstract available

GAFITA A, Rauscher I, Weber M, Hadaschik B, et al
Novel framework for treatment response evaluation using PSMA-PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study.
J Nucl Med. 2022 Apr 14. pii: jnumed.121.263072. doi: 10.2967/jnumed.121.263072.
PubMed Abstract available

KUWERT T, Schmidkonz C, Prante O, Schett G, et al
FAPI-PET Opens a New Window for Understanding of Immune-Mediated Inflammatory Diseases.
J Nucl Med. 2022 Apr 7. pii: jnumed.122.263922. doi: 10.2967/jnumed.122.263922.
PubMed Abstract available

KROENKE M, Schweiger L, Horn T, Haller B, et al
Validation of (18)F-rhPSMA-7 and (18)F-rhPSMA-7.3 PET imaging results with histopathology from salvage surgery in patients with biochemical recurrence of prostate cancer.
J Nucl Med. 2022 Apr 7. pii: jnumed.121.263707. doi: 10.2967/jnumed.121.263707.
PubMed Abstract available

GORDON L
ABNM: Nuclear Medicine In-Training Examination Goes Virtual.
J Nucl Med. 2022;63:18N.
PubMed

SNMMI Calls for Expanded Coverage/Reimbursement of Amyloid PET.
J Nucl Med. 2022;63:17N.
PubMed

PAPPAS V
SNMMI Leadership Update: SNMMI Meetings Back in Full Swing.
J Nucl Med. 2022;63:19N.
PubMed

SNMMI Newsline.
J Nucl Med. 2022;63:15N-26N.
PubMed

NELSON BJB, Ferguson S, Wuest M, Wilson J, et al
First In Vivo and Phantom Imaging of Cyclotron-Produced (133)La as a Theranostic Radionuclide for (225)Ac and (135)La.
J Nucl Med. 2022;63:584-590.
PubMed Abstract available

March 2022

EMMETT LM, Papa N, Buteau J, Ho B, et al
The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis.
J Nucl Med. 2022 Mar 17. pii: jnumed.121.263448. doi: 10.2967/jnumed.121.263448.
PubMed Abstract available

LEE J, Burkett BJ, Min HK, Lundt ES, et al
The Overlap Index as a means of evaluating early tau-PET signal reliability.
J Nucl Med. 2022 Mar 17. pii: jnumed.121.263136. doi: 10.2967/jnumed.121.263136.
PubMed Abstract available

ZARAGORI T, Verger A
Reply to Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study".
J Nucl Med. 2022 Mar 17. pii: jnumed.122.264035. doi: 10.2967/jnumed.122.264035.
PubMed

HOTTA M, Gafita A, Czernin J, Calais J, et al
Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with (177)Lu-PSMA therapy: a multicenter retrospective analysis.
J Nucl Med. 2022 Mar 10. pii: jnumed.121.263441. doi: 10.2967/jnumed.121.263441.
PubMed Abstract available

ILHAN H, Kroenke M, Wurzer A, Unterrainer M, et al
(18)F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer after Curative-intent Radiation Therapy: A Bicentric Retrospective Study.
J Nucl Med. 2022 Mar 10. pii: jnumed.121.262861. doi: 10.2967/jnumed.121.262861.
PubMed Abstract available

SUILAMO S, Li XG, Lankinen P, Oikonen V, et al
(68)Ga-Citrate Positron Emission Tomography of Healthy Men: Whole-Body Biodistribution Kinetics and Radiation Dose Estimates.
J Nucl Med. 2022 Mar 10. pii: jnumed.122.263884. doi: 10.2967/jnumed.122.263884.
PubMed Abstract available

FONTI R, Panico M, Pellegrino S, Pulcrano A, et al
Heterogeneity of SSTR2 expression assessed by (68)Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors.
J Nucl Med. 2022 Mar 10. pii: jnumed.121.262928. doi: 10.2967/jnumed.121.262928.
PubMed Abstract available

PANTEL AR, Mankoff DA, Karp JS
Total Body PET - Will it Change Science and Practice?
J Nucl Med. 2022 Mar 10. pii: jnumed.121.263481. doi: 10.2967/jnumed.121.263481.
PubMed

NOTOHAMIPRODJO S, Eiber M, Lohrmann C, Weber WA, et al
Temporary reactive response of axillary lymph nodes to COVID-19 vaccination on (18)F-rhPSMA-7.3 PET/CT in patients with prostate cancer.
J Nucl Med. 2022 Mar 3. pii: jnumed.121.263758. doi: 10.2967/jnumed.121.263758.
PubMed Abstract available

BUCK AK, Haug A, Dreher N, Lambertini A, et al
Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
PubMed Abstract available

SNMMI Launches Radiopharmaceutical Therapy Centers of Excellence Program.
J Nucl Med. 2022;63:14N.
PubMed

PRASAD V, Boss M, Rottenburger C, Brenner W, et al
Reply: (68)Ga NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
J Nucl Med. 2022;63:493-494.
PubMed

BANERJEE I, Sajjan R, Estebanez MS, Dunne MJ, et al
(68)Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication.
J Nucl Med. 2022;63:493.
PubMed

GULUDEC DL, Czernin J, Calais J
Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jeremie Calais.
J Nucl Med. 2022;63:327-330.
PubMed

TZOLOS E, Kwiecinski J, Berman D, Slomka P, et al
Latest Advances in Multimodality Imaging of Aortic Stenosis.
J Nucl Med. 2022;63:353-358.
PubMed Abstract available

SARI H, Reaungamornrat J, Catalano OA, Vera-Olmos J, et al
Evaluation of Deep Learning-Based Approaches to Segment Bowel Air Pockets and Generate Pelvic Attenuation Maps from CAIPIRINHA-Accelerated Dixon MR Images.
J Nucl Med. 2022;63:468-475.
PubMed Abstract available

DING J, Tong A, Zhang Y, Wen J, et al
Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor.
J Nucl Med. 2022;63:368-375.
PubMed Abstract available

ROTH D, Gustafsson J, Warfvinge CF, Sundlov A, et al
Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with (177)Lu-DOTATATE.
J Nucl Med. 2022;63:399-405.
PubMed Abstract available

EERTINK JJ, Pfaehler EAG, Wiegers SE, van T, et al
Quantitative Radiomics Features in Diffuse Large B-Cell Lymphoma: Does Segmentation Method Matter?
J Nucl Med. 2022;63:389-395.
PubMed Abstract available

LASSEN ML, Byrne C, Sheykhzade M, Wissenberg M, et al
Sex Differences and Caffeine Impact in Adenosine-Induced Hyperemia.
J Nucl Med. 2022;63:431-437.
PubMed Abstract available

VIRGOLINI I, Bahri S, Kjaer A, Gronbaek H, et al
A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for (68)Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med. 2022;63:376-383.
PubMed Abstract available

BAUM RP, Schuchardt C, Singh A, Chantadisai M, et al
Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results.
J Nucl Med. 2022;63:415-423.
PubMed Abstract available

WAHL RL
SNMMI Leadership Update: Call the Nuclear Oncologist.
J Nucl Med. 2022;63:15N.
PubMed

SNMMI Statement: Possible Effect of Omicron Infection on (18)F-FDG-Based Imaging.
J Nucl Med. 2022;63:11N.
PubMed

SNMMI Newsline.
J Nucl Med. 2022;63:11N-22N.
PubMed

February 2022

LEITHNER D, Schoder H, Haug AR, Vargas HA, et al
Impact of ComBat harmonization on PET radiomics-based tissue classification: a dual-center PET/MR and PET/CT study.
J Nucl Med. 2022 Feb 24. pii: jnumed.121.263102. doi: 10.2967/jnumed.121.263102.
PubMed Abstract available

YANG Z, Li F, Huang Y, Yin N, et al
Dynamic Tumor-Specific MHC-II Immuno-PET Predicts Checkpoint Inhibitor Immunotherapy Efficacy in Melanoma.
J Nucl Med. 2022 Feb 24. pii: jnumed.121.263151. doi: 10.2967/jnumed.121.263151.
PubMed Abstract available

LUCOT KL, Stevens MY, Bonham TA, Azevedo EC, et al
TRACKING INNATE IMMUNE ACTIVATION IN A MOUSE MODEL OF PARKINSON'S DISEASE USING TREM1 AND TSPO PET TRACERS.
J Nucl Med. 2022 Feb 17. pii: jnumed.121.263039. doi: 10.2967/jnumed.121.263039.
PubMed Abstract available

WU WY, Yu F, Zhang PJ, Bu T, et al
(68)Ga-DOTA-NT-20.3 Neurotensin receptor 1 positron emission tomography imaging as a surrogate for neuroendocrine differentiation of prostate cancer.
J Nucl Med. 2022 Feb 17. pii: jnumed.121.263132. doi: 10.2967/jnumed.121.263132.
PubMed Abstract available

FORAY C, Barca C, Winkeler A, Wagner S, et al
Interrogating glioma-associated microglia/macrophage dynamics under CSF-1R therapy with multi-tracer in vivo PET/MR imaging.
J Nucl Med. 2022 Feb 3. pii: jnumed.121.263318. doi: 10.2967/jnumed.121.263318.
PubMed Abstract available

BARCA C, Kiliaan AJ, Wachsmuth L, Foray C, et al
Short-term colony stimulating factor-1 receptor inhibition-induced repopulation after stroke assessed by longitudinal (18)F-DPA-714 PET imaging.
J Nucl Med. 2022 Feb 3. pii: jnumed.121.263004. doi: 10.2967/jnumed.121.263004.
PubMed Abstract available

ZHANG X, Li M, Gai Y, Chen J, et al
(18)F-PFPN PET: a new and attractive imaging modality for patients with malignant melanoma.
J Nucl Med. 2022 Feb 3. pii: jnumed.121.263179. doi: 10.2967/jnumed.121.263179.
PubMed Abstract available

ZANOTTI-FREGONARA P, Ishiguro T, Yoshihara K, Ishii S, et al
(18)F-FDG Fetal Dosimetry Calculated with PET/MRI.
J Nucl Med. 2022 Feb 3. pii: jnumed.121.263561. doi: 10.2967/jnumed.121.263561.
PubMed Abstract available

FDA Approves New (68)Ga Kit for Prostate Cancer PET.
J Nucl Med. 2022;63:26N.
PubMed

WAHL RL
SNMMI to Host Summits on Artificial Intelligence and Patient Access.
J Nucl Med. 2022;63:27N.
PubMed

ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
J Nucl Med. 2022;63:218-225.
PubMed Abstract available

GILLESSEN S, Czernin J, Herrmann K
A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann.
J Nucl Med. 2022;63:169-171.
PubMed

ORLHAC F, Eertink JJ, Cottereau AS, Zijlstra JM, et al
A Guide to ComBat Harmonization of Imaging Biomarkers in Multicenter Studies.
J Nucl Med. 2022;63:172-179.
PubMed Abstract available

KHODAII J, Araj-Khodaei M, Vafaee MS, Wong DF, et al
Relative Strengths of Three Linearizations of Receptor Availability: Saturation, Inhibition, and Occupancy Plots.
J Nucl Med. 2022;63:294-301.
PubMed Abstract available

ZHANG Y, Kupferschlaeger J, Lang P, Reischl G, et al
(131)I-GD2-ch14.18 Scintigraphy to Evaluate Option for Radioimmunotherapy in Patients with Advanced Tumors.
J Nucl Med. 2022;63:205-211.
PubMed Abstract available

January 2022

VILEMAGNE VL, Harada R, Dore V, Furumoto S, et al
First-in-human evaluation of (18)F-SMBT-1, a novel (18)F-labeled MAO-B PET tracer for imaging reactive astrogliosis.
J Nucl Med. 2022 Jan 27. pii: jnumed.121.263254. doi: 10.2967/jnumed.121.263254.
PubMed Abstract available

ALBERGE JB, Kraeber-Bodere F, Jamet B, Touzeau C, et al
Molecular signature of FDG-PET biomarkers in newly diagnosed multiple myeloma patients: a genome-wide transcriptome analysis from the CASSIOPET study.
J Nucl Med. 2022 Jan 27. pii: jnumed.121.262884. doi: 10.2967/jnumed.121.262884.
PubMed Abstract available

SPANGLER-BICKELL MG, Hurley SA, Pirasteh A, Perlman SB, et al
Evaluation of Data-Driven Rigid Motion Correction in Clinical Brain PET Imaging.
J Nucl Med. 2022 Jan 27. pii: jnumed.121.263309. doi: 10.2967/jnumed.121.263309.
PubMed Abstract available

KUO PH, Benson T, Messmann R, Groaning M, et al
Why We Did What We Did: PSMA-PET/CT Selection Criteria for the VISION Trial.
J Nucl Med. 2022 Jan 27. pii: jnumed.121.263638. doi: 10.2967/jnumed.121.263638.
PubMed

SEO M, Kim Y, Ye BD, Park SH, et al
Positron emission tomography imaging of system xc(-) in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease.
J Nucl Med. 2022 Jan 27. pii: jnumed.121.263289. doi: 10.2967/jnumed.121.263289.
PubMed Abstract available

LANGEN KJ, Mottaghy FM
Letter to the Editor: "(18)F-FDOPA PET for the Noninvasive Prediction of Glioma Molecular Parameters: A Radiomics Study" [J Nucl Med 2022; 63:147-157].
J Nucl Med. 2022 Jan 27. pii: jnumed.122.263837. doi: 10.2967/jnumed.122.263837.
PubMed

WESTDORP H, Verhoeff SR, Gotthardt M, van Herpen CML, et al
Towards a better understanding of immune checkpoint inhibitor radiolabeled PET imaging studies.
J Nucl Med. 2022 Jan 20. pii: jnumed.121.262622. doi: 10.2967/jnumed.121.262622.
PubMed

NG M, Guerrieri M, Wong LM, Taubman K, et al
The change in management by (18)F-DCFPyL PSMA PET scanning in patients undergoing post-prostatectomy radiotherapy, with early biochemical response outcomes.
J Nucl Med. 2022 Jan 20. pii: jnumed.121.263521. doi: 10.2967/jnumed.121.263521.
PubMed Abstract available

CARLSEN EA, Loft M, Loft A, Berthelsen AK, et al
Prospective phase II trial of prognostication by (68)Ga-NOTA-AE105 uPAR PET in patients with neuroendocrine neoplasms: Implications for uPAR targeted therapy.
J Nucl Med. 2022 Jan 20. pii: jnumed.121.263177. doi: 10.2967/jnumed.121.263177.
PubMed Abstract available

BUNNING S, Ignace C, Mattmuller S, Schwarz SW, et al
Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.
J Nucl Med. 2022 Jan 20. pii: jnumed.121.263443. doi: 10.2967/jnumed.121.263443.
PubMed Abstract available

PRIVE BM, Peters S, Uijen MJM, Janssen MJR, et al
Letter to the Editor RE: Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
J Nucl Med. 2022 Jan 13. pii: jnumed.122.263802. doi: 10.2967/jnumed.122.263802.
PubMed

BERTOGLIO D, Halloin N, De Lombaerde S, Jankovski A, et al
SV2A PET imaging is a non-invasive marker for the detection of spinal damages in experimental models of spinal cord injury.
J Nucl Med. 2022 Jan 13. pii: jnumed.121.263222. doi: 10.2967/jnumed.121.263222.
PubMed Abstract available

LANGBEIN T, Wang H, Rauscher I, Kronke M, et al
Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
J Nucl Med. 2022 Jan 6. pii: jnumed.121.263440. doi: 10.2967/jnumed.121.263440.
PubMed Abstract available

DRIESSEN J, Zwezerijnen GJ, Schoder H, Drees EE, et al
The impact of semi-automatic segmentation methods on metabolic tumor volume, intensity and dissemination radiomics in (18)F-FDG PET scans of patients with classical Hodgkin lymphoma.
J Nucl Med. 2022 Jan 6. pii: jnumed.121.263067. doi: 10.2967/jnumed.121.263067.
PubMed Abstract available

WAHL RL
Ensuring Quality and Safety in Nuclear Medicine Imaging and Therapy.
J Nucl Med. 2022;63:18N.
PubMed

CHEN R, Wang Y, Zhu Y, Shi Y, et al
The Added Value of (18)F-FDG PET/CT Compared with (68)Ga-PSMA PET/CT in Patients with Castration-Resistant Prostate Cancer.
J Nucl Med. 2022;63:69-75.
PubMed Abstract available

HICKS R, Czernin J, Herrmann K
Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann.
J Nucl Med. 2022;63:1-4.
PubMed

December 2021

KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
PubMed Abstract available

LI E, Spencer BA, Schmall JP, Abdelhafez Y, et al
Efficient delay correction for total-body PET kinetic modeling using pulse timing methods.
J Nucl Med. 2021 Dec 21. pii: jnumed.121.262968. doi: 10.2967/jnumed.121.262968.
PubMed Abstract available

CHOI YJ, Koh Y, Lee HJ, Hwang IC, et al
Independent Prognostic Utility of (11)C-Pittsburgh Compound B Positron Emission Tomography in Light-Chain Cardiac Amyloidosis Patients.
J Nucl Med. 2021 Dec 16. pii: jnumed.121.263033. doi: 10.2967/jnumed.121.263033.
PubMed Abstract available

MENA E, Rowe SP, Shih JH, Lindenberg L, et al
Predictors of (18)F-DCFPyL-PET/CT Positivity in Patients with Biochemical Recurrence of Prostate Cancer After Local Therapy.
J Nucl Med. 2021 Dec 16. pii: jnumed.121.262347. doi: 10.2967/jnumed.121.262347.
PubMed Abstract available

ZEYDAN B, Schwarz CG, Przybelski SA, Lesnick TG, et al
Comparison of (11)C-Pittsburgh compound-B and (18)F-Flutemetamol White Matter Binding in PET.
J Nucl Med. 2021 Dec 16. pii: jnumed.121.263281. doi: 10.2967/jnumed.121.263281.
PubMed Abstract available

LI C, Han C, Duan S, Li P, et al
Visualizing T cell responses: The T cell PET imaging toolbox.
J Nucl Med. 2021 Dec 9. pii: jnumed.121.261976. doi: 10.2967/jnumed.121.261976.
PubMed Abstract available

FRIEDMAN NC
The Will Rodgers Phenomenon and PSMA PET/CT.
J Nucl Med. 2021 Dec 9. pii: jnumed.121.263556. doi: 10.2967/jnumed.121.263556.
PubMed

CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
PubMed Abstract available

SCHUCHARDT C, Zhang J, Kulkarni HR, Chen X, et al
Prostate-specific membrane antigen radioligand therapy using (177)Lu-PSMA I&T and (177)Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, biodistribution and dosimetry.
J Nucl Med. 2021 Dec 9. pii: jnumed.121.262713. doi: 10.2967/jnumed.121.262713.
PubMed Abstract available

SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
PubMed Abstract available

MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
PubMed Abstract available

BOUDOUSQ V, Guignard N, Gilly O, Chambert B, et al
Diagnostic performances of cervical ultrasound, sestamibi scintigraphy and contrast-enhanced (18)F-fluorocholine positron emission tomography in primary hyperparathyroidism.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.261900. doi: 10.2967/jnumed.121.261900.
PubMed Abstract available

RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
PubMed Abstract available

BARRINGTON SF, Mir F, El-Galaly TC, Knapp A, et al
Follicular lymphoma treated with first-line immunochemotherapy: a review of PET-CT in patients who did not achieve CMR in the GALLIUM study.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.262869. doi: 10.2967/jnumed.121.262869.
PubMed Abstract available

PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
PubMed Abstract available

LASSMANN M, Eberlein U, Gear J, Konijnenberg M, et al
Dosimetry for Radiopharmaceutical Therapy: The European Perspective.
J Nucl Med. 2021;62.
PubMed Abstract available

PANDIT-TASKAR N, Iravani A, Lee D, Jacene H, et al
Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.
J Nucl Med. 2021;62.
PubMed Abstract available

GRAVES SA, Bageac A, Crowley JR, Merlino DAM, et al
Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities.
J Nucl Med. 2021;62.
PubMed Abstract available

CAPALA J, Graves SA, Scott A, Sgouros G, et al
Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources.
J Nucl Med. 2021;62.
PubMed Abstract available

WAHL RL, Sgouros G, Iravani A, Jacene H, et al
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns.
J Nucl Med. 2021;62.
PubMed

WAHL RL, Sunderland J
Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice.
J Nucl Med. 2021;62.
PubMed

SGOUROS G, Dewaraja YK, Escorcia F, Graves SA, et al
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.
J Nucl Med. 2021;62.
PubMed Abstract available

URIBE C, Peterson A, Van B, Fedrigo R, et al
An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 1: Design and Early Results of the SNMMI Dosimetry Challenge.
J Nucl Med. 2021;62.
PubMed Abstract available

November 2021

COSTA GCA, Spencer BA, Omidvari N, Foster C, et al
Radioembolization Dosimetry with Total-Body (90)Y PET.
J Nucl Med. 2021 Nov 18. pii: jnumed.121.263145. doi: 10.2967/jnumed.121.263145.
PubMed Abstract available

WANG G, Nardo L, Parikh M, Abdelhafez YG, et al
Total-Body PET Multiparametric Imaging of Cancer Using a Voxel-wise Strategy of Compartmental Modeling.
J Nucl Med. 2021 Nov 18. pii: jnumed.121.262668. doi: 10.2967/jnumed.121.262668.
PubMed Abstract available

MALPETTI M, Kaalund SS, Tsvetanov KA, Rittman T, et al
In vivo (18)F-flortaucipir PET does not accurately support the staging of progressive supranuclear palsy.
J Nucl Med. 2021 Nov 18. pii: jnumed.121.262985. doi: 10.2967/jnumed.121.262985.
PubMed Abstract available

THEISEN AL, Lassmann M, Tran-Gia J
Towards a patient-specific traceable quantification of SPECT/CT-based radiopharmaceutical distributions.
J Nucl Med. 2021 Nov 18. pii: jnumed.121.262925. doi: 10.2967/jnumed.121.262925.
PubMed Abstract available

REDDY RP, Schmidtlein CR, Giancipoli RG, Mauguen A, et al
The quest for an accurate functional tumor volume with (68)Ga-DOTATATE PET/CT.
J Nucl Med. 2021 Nov 12. pii: jnumed.121.262782. doi: 10.2967/jnumed.121.262782.
PubMed Abstract available

STELLA M, van Rooij R, Lam M, de Jong H, et al
Lung dose measured on post-radioembolization (90)Y-PET/CT and incidence of radiation pneumonitis.
J Nucl Med. 2021 Nov 12. pii: jnumed.121.263143. doi: 10.2967/jnumed.121.263143.
PubMed Abstract available

SHAGERA QA, Artigas C, Karfis I, Critchi G, et al
(68)Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
J Nucl Med. 2021 Nov 12. pii: jnumed.121.263006. doi: 10.2967/jnumed.121.263006.
PubMed Abstract available

MONA CE, Benz MR, Hikmat F, Grogan TR, et al
Correlation of (68)Ga-FAPi-46 PET biodistribution with FAP expression by immunohistochemistry in patients with solid cancers: a prospective translational exploratory study.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.262426. doi: 10.2967/jnumed.121.262426.
PubMed Abstract available

BRADSHAW TJ, Boellaard R, Dutta J, Jha AK, et al
Nuclear Medicine and Artificial Intelligence: Best Practices for Algorithm Development.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.262567. doi: 10.2967/jnumed.121.262567.
PubMed Abstract available

YOUNIS MH, Lan X, Cai W
PET with a (68)Ga-labeled FAPI dimer: moving towards theranostics.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.263292. doi: 10.2967/jnumed.121.263292.
PubMed

THUILLIER P, Liberini V, Grimaldi S, Rampado O, et al
Prognostic value of whole-body PET volumetric parameters extracted from (68)Ga-DOTATOC-PET/CT in well-differentiated neuroendocrine tumors.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.262652. doi: 10.2967/jnumed.121.262652.
PubMed Abstract available

KESNER AL
Commercially competitive vendor-agnostic image reconstruction could be a leap forward for PET harmonization.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.263421. doi: 10.2967/jnumed.121.263421.
PubMed

NIMMAGADDA S
Imaging PD-L1 expression in melanoma brain metastases.
J Nucl Med. 2021 Nov 5. pii: jnumed.121.263209. doi: 10.2967/jnumed.121.263209.
PubMed

SCOTT AM, Czernin J
Perspectives on Theranostics and Nuclear Medicine: A Conversation Between Andrew Scott and Johannes Czernin.
J Nucl Med. 2021;62:1492-1494.
PubMed

CALAIS J, Czernin J
PSMA Expression Assessed by PET Imaging Is a Required Biomarker for Selecting Patients for Any PSMA-Targeted Therapy.
J Nucl Med. 2021;62:1489-1491.
PubMed

PARKER MFL, Blecha J, Rosenberg O, Ohliger M, et al
Cyclic (68)Ga-Labeled Peptides for Specific Detection of Human Angiotensin-Converting Enzyme 2.
J Nucl Med. 2021;62:1631-1637.
PubMed Abstract available

HORSAGER J, Knudsen K, Borghammer P
Radionuclide Imaging of the Gut-Brain Axis in Parkinson Disease.
J Nucl Med. 2021;62:1504-1505.
PubMed

MILLER RJH, Sharir T, Otaki Y, Gransar H, et al
Quantitation of Poststress Change in Ventricular Morphology Improves Risk Stratification.
J Nucl Med. 2021;62:1582-1590.
PubMed Abstract available

BAUM RP, Zhang J, Schuchardt C, Muller D, et al
First-in-Humans Study of the SSTR Antagonist (177)Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.
J Nucl Med. 2021;62:1571-1581.
PubMed Abstract available

PARGHANE RV, Bhandare M, Chaudhari V, Ostwal V, et al
Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant (177)Lu-DOTATATE PRRT for Locally Advanced Unresectable Gastroenteropancreatic Neuroendocrine Tumors.
J Nucl Med. 2021;62:1558-1563.
PubMed Abstract available

ZHOU Z, Meshaw R, Zalutsky MR, Vaidyanathan G, et al
Site-Specific and Residualizing Linker for (18)F Labeling with Enhanced Renal Clearance: Application to an Anti-HER2 Single-Domain Antibody Fragment.
J Nucl Med. 2021;62:1624-1630.
PubMed Abstract available

October 2021

YUSUFALY T, Zou J, Nelson T, Williamson C, et al
Improved Prognosis of Treatment Failure in Cervical Cancer with Non-Tumor Positron Emission Tomography / Computed Tomography Radiomics.
J Nucl Med. 2021 Oct 28. pii: jnumed.121.262618. doi: 10.2967/jnumed.121.262618.
PubMed Abstract available

AHLMAN MA, Maass-Moreno R, Grayson PC peter.gray
Reply LTE, On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessel Vasculitis.
J Nucl Med. 2021 Oct 28. pii: jnumed.121.263158. doi: 10.2967/jnumed.121.263158.
PubMed

BURGGRAAFF CN, Eertink JJ, Lugtenburg PJ, Hoekstra OS, et al
(18)F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: The HOVON-84 study.
J Nucl Med. 2021 Oct 21. pii: jnumed.121.262205. doi: 10.2967/jnumed.121.262205.
PubMed Abstract available

GHEYSENS O, Belkhir L, Jamar F
Imaging in Post-COVID Lung Disease (PCLD): does [(18)F]-FDG-PET/CT have the Key?
J Nucl Med. 2021 Oct 21. pii: jnumed.121.263166. doi: 10.2967/jnumed.121.263166.
PubMed

LASNON C, Girault G, Lebtahi R, Ansquer C, et al
Women Authors in Nuclear Medicine Journals: a Survey from 2014 to 2020.
J Nucl Med. 2021 Oct 21. pii: jnumed.121.262773. doi: 10.2967/jnumed.121.262773.
PubMed Abstract available

MIYAHIRA AK, Soule HR
The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Foundational Role of the Prostate Cancer Foundation.
J Nucl Med. 2021 Oct 21. pii: jnumed.121.262997. doi: 10.2967/jnumed.121.262997.
PubMed Abstract available

SCHMIDKONZ C
Perspective on Fibroblast Activation Protein Specific PET/CT Imaging in Fibrotic Interstitial Lung Diseases: Imaging Fibrosis - a New Paradigm for Molecular Imaging?
J Nucl Med. 2021 Oct 14. pii: jnumed.121.262944. doi: 10.2967/jnumed.121.262944.
PubMed

SONNI I, Felker ER, Lenis AT, Sisk AE, et al
Head-to-head comparison of (68)Ga-PSMA-11 PET/CT and mpMRI with histopathology gold-standard in the detection, intra-prostatic localization and local extension of primary prostate cancer: results from a prospective single-center imaging trial.
J Nucl Med. 2021 Oct 14. pii: jnumed.121.262398. doi: 10.2967/jnumed.121.262398.
PubMed Abstract available

LE ROUX PY, Bonnefoy PB, Bahloul A, Denizot B, et al
Lung scintigraphy for pulmonary embolism diagnosis in COVID-19 patients: a multicenter study.
J Nucl Med. 2021 Oct 14. pii: jnumed.121.262955. doi: 10.2967/jnumed.121.262955.
PubMed Abstract available

RISCHKA L, Vraka C, Pichler V, Rasul S, et al
First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-(11)C-Me-NB1.
J Nucl Med. 2021 Oct 7. pii: jnumed.121.262427. doi: 10.2967/jnumed.121.262427.
PubMed Abstract available

FERDINANDUS J, Fendler WP, Farolfi A, Washington S, et al
PSMA PET validates higher rates of metastatic disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study.
J Nucl Med. 2021 Oct 7. pii: jnumed.121.262821. doi: 10.2967/jnumed.121.262821.
PubMed Abstract available

KESSLER L, Ferdinandus J, Hirmas N, Zarrad F, et al
Pitfalls and common findings in (68)Ga-FAPI-PET - A pictorial analysis.
J Nucl Med. 2021 Oct 7. pii: jnumed.121.262808. doi: 10.2967/jnumed.121.262808.
PubMed Abstract available

MAHAJAN S, Barker CA, Mauguen A, D'Angelo SP, et al
(18)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma.
J Nucl Med. 2021 Oct 7. pii: jnumed.121.262882. doi: 10.2967/jnumed.121.262882.
PubMed Abstract available

BARATTO L, Hawk KE, States L, Qi J, et al
PET/MRI Improves Management of Children with Cancer.
J Nucl Med. 2021;62:1334-1340.
PubMed Abstract available

JOHNSON BJ, Van Abel KM, Ma DJ, Johnson DR, et al
(18)F-FDG-Avid Axillary Lymph Nodes After COVID-19 Vaccination.
J Nucl Med. 2021;62:1483-1484.
PubMed

PARK S, Parihar AS, Bodei L, Hope TA, et al
Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
J Nucl Med. 2021;62:1323-1329.
PubMed Abstract available

BERGER DMS, van den Berg NS, van der Noort V, van der Hiel B, et al
Technologic (R)Evolution Leads to Detection of More Sentinel Nodes in Patients with Melanoma in the Head and Neck Region.
J Nucl Med. 2021;62:1357-1362.
PubMed Abstract available

ZHU W, Cheng Y, Jia R, Zhao H, et al
A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of (68)Ga-NODAGA-LM3 and (68)Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors.
J Nucl Med. 2021;62:1398-1405.
PubMed Abstract available

September 2021

TAHERPOUR J, Jaber M, Voges B, Apostolova I, et al
Predicting the outcome of epilepsy surgery by covariance pattern analysis of ictal perfusion SPECT.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262702. doi: 10.2967/jnumed.121.262702.
PubMed Abstract available

XU M, Zhang P, Ding J, Chen J, et al
Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262533. doi: 10.2967/jnumed.121.262533.
PubMed Abstract available

PALESTRO C, Clark A, Grady E, Heiba S, et al
Appropriate Use Criteria for the Use of Nuclear Medicine in Musculoskeletal Infection Imaging.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262579. doi: 10.2967/jnumed.121.262579.
PubMed

CROMPTON J, Armstrong WR, Eckardt MA, Seyedroudbari A, et al
(18)F-FLT PET/CT as a prognostic imaging biomarker of disease specific survival in patients with primary soft tissue sarcoma.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262502. doi: 10.2967/jnumed.121.262502.
PubMed Abstract available

JADVAR H, Calais J, Fanti S, Feng F, et al
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.263262. doi: 10.2967/jnumed.121.263262.
PubMed

GU B, Xu X, Zhang J, Ou X, et al
The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
PubMed Abstract available

HU Y, Liu G, Yu H, Wang Y, et al
Feasibility of ultra-low (18)F-FDG activity acquisitions using total-body PET/CT.
J Nucl Med. 2021 Sep 30. pii: jnumed.121.262038. doi: 10.2967/jnumed.121.262038.
PubMed Abstract available

ZHAO L, Niu B, Fang J, Pang Y, et al
Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer.
J Nucl Med. 2021 Sep 23. pii: jnumed.121.263016. doi: 10.2967/jnumed.121.263016.
PubMed Abstract available

WEBER M, Schmitz J, Maric I, Pabst KM, et al
Diagnostic performance of [(124)I]m-iodobenzylguanidine PET/CT in patients with pheochromocytoma.
J Nucl Med. 2021 Sep 23. pii: jnumed.121.262797. doi: 10.2967/jnumed.121.262797.
PubMed Abstract available

SONG H, Iagaru A, Rowe SP
(18)F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
J Nucl Med. 2021 Sep 16. pii: jnumed.121.262989. doi: 10.2967/jnumed.121.262989.
PubMed Abstract available

NIENHUIS PH, Antunes IF, Glaudemans AWJM, Jalving M, et al
(18)F-BMS986192 PET imaging of PD-L1 in metastatic melanoma patients with brain metastases treated with immune checkpoint inhibitors. A pilot study.
J Nucl Med. 2021 Sep 9. pii: jnumed.121.262368. doi: 10.2967/jnumed.121.262368.
PubMed Abstract available

ZANOVELLO M, Soraru G, Campi C, Anglani M, et al
Brainstem glucose hypermetabolism in ALS/FTD and shorten survival: a (18)F-FDG PET/MR study.
J Nucl Med. 2021 Sep 9. pii: jnumed.121.262232. doi: 10.2967/jnumed.121.262232.
PubMed Abstract available

MHLANGA J, Haq A, Derenoncourt P, Bhandiwad A, et al
(18)F-FDG Positron Emission Tomography in Myocardial Viability Assessment: A Practical and Time Efficient Protocol.
J Nucl Med. 2021 Sep 9. pii: jnumed.121.262432. doi: 10.2967/jnumed.121.262432.
PubMed Abstract available

LAFFON E, Marthan R
On Semi-quantitative Methods for Assessing Vascular (18)FDG-PET Activity in Large-Vessels Vasculitis.
J Nucl Med. 2021 Sep 2. pii: jnumed.121.263060. doi: 10.2967/jnumed.121.263060.
PubMed

FOURQUET A, Rosenberg A, Mena E, Shih JJ, et al
A comparison of (18)F-DCFPyL, (18)F-NaF and (18)F-FDG PET/CT in a prospective cohort of men with metastatic prostate cancer.
J Nucl Med. 2021 Sep 2. pii: jnumed.121.262371. doi: 10.2967/jnumed.121.262371.
PubMed Abstract available

CARRASQUILLO JA, Chen CC, Jha A, Pacak K, et al
Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma.
J Nucl Med. 2021;62:1192-1199.
PubMed Abstract available

CZERNIN J, Radu C, Ribas A
Leadership Focus on Advancing Cancer Research and Treatment: A Conversation Between Johannes Czernin, Caius Radu, and Antoni Ribas.
J Nucl Med. 2021;62:1178-1180.
PubMed

JALLINOJA VIJ, Houghton JL
Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy.
J Nucl Med. 2021;62:1200-1206.
PubMed Abstract available

August 2021

SEIFERT R, Sandach P, Kersting D, Fendler WP, et al
Repeatability of (68)Ga-PSMA-HBED-CC PET/CT-derived total molecular tumor volume.
J Nucl Med. 2021 Aug 26. pii: jnumed.121.262528. doi: 10.2967/jnumed.121.262528.
PubMed Abstract available

BAG AK, Wing MN, Sabin ND, Hwang SN, et al
[(11)C]-Methionine PET for Identification of Pediatric High-Grade Glioma Recurrence.
J Nucl Med. 2021 Aug 26. pii: jnumed.120.261891. doi: 10.2967/jnumed.120.261891.
PubMed Abstract available

IQBAL R, Yaqub M, Oprea-Lager DE, Liu Y, et al
Biodistribution of (18)F-FES in patients with metastatic ER+ breast cancer undergoing treatment with Rintodestrant (G1T48), a novel selective estrogen receptor degrader.
J Nucl Med. 2021 Aug 26. pii: jnumed.121.262500. doi: 10.2967/jnumed.121.262500.
PubMed Abstract available

LO AC, James LP, Prica A, Raymakers A, et al
Positron-emission tomography-based staging is cost-effective in early-stage follicular lymphoma.
J Nucl Med. 2021 Aug 19. pii: jnumed.121.262324. doi: 10.2967/jnumed.121.262324.
PubMed Abstract available

FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
PubMed Abstract available

PARIHAR AS, Schmidt LR, Dehdashti F, Wahl RL, et al
Detection of additional primary neoplasms on (18)F-Fluciclovine PET/CT in patients with primary prostate cancer.
J Nucl Med. 2021 Aug 19. pii: jnumed.121.262647. doi: 10.2967/jnumed.121.262647.
PubMed Abstract available

PAQUETTE M, Espinosa-Bentancourt E, Lavallee E, Phoenix S, et al
(18)F-4FMFES and (18)F-FDG PET/CT in ER+ endometrial carcinomas: preliminary report.
J Nucl Med. 2021 Aug 19. pii: jnumed.121.262617. doi: 10.2967/jnumed.121.262617.
PubMed Abstract available

MATHEY C, Keyzer C, Blocklet D, Van Simaeys G, et al
(18)F-fluorocholine PET/CT is more sensitive than (11)C-methionine PET/CT for the localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism.
J Nucl Med. 2021 Aug 19. pii: jnumed.121.262395. doi: 10.2967/jnumed.121.262395.
PubMed Abstract available

SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
PubMed Abstract available

HOFMAN MS
Bringing VISION to Nuclear Medicine: accelerating evidence and changing paradigms with theranostics.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262890. doi: 10.2967/jnumed.121.262890.
PubMed

LANGBEIN T, Wurzer A, Gafita A, Robertson A, et al
The Influence of Specific Activity on the Biodistribution of (18)F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262471. doi: 10.2967/jnumed.121.262471.
PubMed Abstract available

LU P, Benabdallah N, Jiang W, Simons BW, et al
Blind Image Restoration Enhances Digital Autoradiographic Imaging of Radiopharmaceutical Tissue Distribution.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262270. doi: 10.2967/jnumed.121.262270.
PubMed Abstract available

NAGANAWA M, Nabulsi NB, Matuskey D, Henry S, et al
Imaging pituitary vasopressin 1B receptor in humans with the novel PET radiotracer (11)C-TASP699.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262430. doi: 10.2967/jnumed.121.262430.
PubMed Abstract available

FENG T, Wu Y, Zhao Y, Xu T, et al
Whole-body Parametric Imaging of FDG PET using uEXPLORER with Reduced Scan Time.
J Nucl Med. 2021 Aug 12. pii: jnumed.120.261651. doi: 10.2967/jnumed.120.261651.
PubMed Abstract available

BRAGINA O, Chernov V, Schulga A, Konovalova E, et al
Phase I trial of (99m)Tc-(HE)3-G3, a DARPin-based probe for imaging of HER2 expression in breast cancer.
J Nucl Med. 2021 Aug 12. pii: jnumed.121.262542. doi: 10.2967/jnumed.121.262542.
PubMed Abstract available

STABIN MG, Wendt RE 3rd, Flux GD
RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 1. Collection of Data for Radiopharmaceutical Dosimetry.
J Nucl Med. 2021 Aug 5. pii: jnumed.120.259200. doi: 10.2967/jnumed.120.259200.
PubMed Abstract available

STABIN MG, Wendt RE 3rd, Flux GD
RADAR Guide: Standard Methods for Calculating Radiation Doses for Radiopharmaceuticals Part 2. Data Analysis and Dosimetry.
J Nucl Med. 2021 Aug 5. pii: jnumed.121.262034. doi: 10.2967/jnumed.121.262034.
PubMed Abstract available

BRENDLE C, Maier C, Bender B, Schittenhelm J, et al
Impact of (18)F-FET PET/MR on clinical management of brain tumor patients.
J Nucl Med. 2021 Aug 5. pii: jnumed.121.262051. doi: 10.2967/jnumed.121.262051.
PubMed Abstract available

IAGARU A
2021 SNMMI Highlights Lecture: General Nuclear Medicine.
J Nucl Med. 2021;62:12N-17N.
PubMed

FDA Approves (18)F-DCFPyL PET Agent in Prostate Cancer.
J Nucl Med. 2021;62:11N.
PubMed

CZERNIN J, Calais J
(177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
J Nucl Med. 2021;62:1025-1026.
PubMed

CARRASQUILLO JA, Chen CC, Jha A, Ling A, et al
Imaging of Pheochromocytoma and Paraganglioma.
J Nucl Med. 2021;62:1033-1042.
PubMed Abstract available

HOFMAN MS, Calais J, Czernin J
Perspectives on Cutting-Edge Clinical Trials: A Conversation Between Michael Hofman, Johannes Czernin, and Jeremie Calais.
J Nucl Med. 2021;62:1027-1030.
PubMed

WAHL RL, Dilsizian V, Palestro CJ
At Last, (18)F-FDG for Inflammation and Infection!
J Nucl Med. 2021;62:1048-1049.
PubMed

CLEMENTE GS, Antunes IF, Kurhade S, van den Berg MPM, et al
Mapping Arginase Expression with (18)F-Fluorinated Late-Generation Arginase Inhibitors Derived from Quaternary alpha-Amino Acids.
J Nucl Med. 2021;62:1163-1170.
PubMed Abstract available

FERNANDEZ R, Eppard E, Lehnert W, Jimenez-Franco LD, et al
Evaluation of Safety and Dosimetry of (177)Lu-DOTA-ZOL for Therapy of Bone Metastases.
J Nucl Med. 2021;62:1126-1132.
PubMed Abstract available

LASSEN ML, Otaki Y, Kavanagh P, Miller RJH, et al
Simulation of Low-Dose Protocols for Myocardial Perfusion (82)Rb Imaging.
J Nucl Med. 2021;62:1112-1117.
PubMed Abstract available

URBAN S, Meyer C, Dahlbom M, Farkas I, et al
Radiation Dosimetry of (99m)Tc-PSMA I&S: A Single-Center Prospective Study.
J Nucl Med. 2021;62:1075-1081.
PubMed Abstract available

July 2021

DIETLEIN F, Kobe C, Munoz Vazquez S, Fischer T, et al
An (89)Zr-labeled PSMA tracer for PET/CT imaging of prostate cancer patients.
J Nucl Med. 2021 Jul 29. pii: jnumed.121.262290. doi: 10.2967/jnumed.121.262290.
PubMed Abstract available

DONG L, Su Y, Zhu Y, Markowski MC, et al
The European Association of Urology Biochemical Recurrence Risk Groups Predict Findings on PSMA PET in Patients with Biochemically Recurrent Prostate Cancer after Radical Prostatectomy.
J Nucl Med. 2021 Jul 29. pii: jnumed.121.262411. doi: 10.2967/jnumed.121.262411.
PubMed Abstract available

ABGHARI-GERST M, Armstrong WR, Nguyen K, Calais J, et al
A comprehensive assessment of (68)Ga-PSMA-11 PET in biochemically recurrent prostate cancer: Results from a prospective multi-center study in 2005 patients.
J Nucl Med. 2021 Jul 29. pii: jnumed.121.262412. doi: 10.2967/jnumed.121.262412.
PubMed Abstract available

ZHOU X, Jiang J, Yang X, Liu T, et al
First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
PubMed Abstract available

PATHMANANDAVEL S, Crumbaker M, Yam AO, Nguyen A, et al
(177)Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.
J Nucl Med. 2021 Jul 29. pii: jnumed.121.262552. doi: 10.2967/jnumed.121.262552.
PubMed Abstract available

WOFF E, Salvatore L, Marmorino F, Genovesi D, et al
Combined Metabolically Active Tumor Volume and Early Metabolic Response Improve Outcome Prediction in Metastatic Colorectal Cancer.
J Nucl Med. 2021 Jul 29. pii: jnumed.120.245357. doi: 10.2967/jnumed.120.245357.
PubMed Abstract available

CATANA C, Laforest R, An H, Boada F, et al
A Path to Qualification of PET/MR Scanners for Multicenter Brain Imaging Studies: Evaluation of MR-based Attenuation Correction Methods Using a Patient Phantom.
J Nucl Med. 2021 Jul 22. pii: jnumed.120.261881. doi: 10.2967/jnumed.120.261881.
PubMed Abstract available

PRENOSIL GA, Sari H, Furstner M, Afshar-Oromieh A, et al
Performance Characteristics of the Biograph Vision Quadra PET/CT system with long axial field of view using the NEMA NU 2-2018 Standard.
J Nucl Med. 2021 Jul 22. pii: jnumed.121.261972. doi: 10.2967/jnumed.121.261972.
PubMed Abstract available

OREVI M, Chicheportiche A, Ben-Haim S
Lessons learned from post-COVID-19 vaccination PET/CT studies.
J Nucl Med. 2021 Jul 22. pii: jnumed.121.262348. doi: 10.2967/jnumed.121.262348.
PubMed Abstract available

GANS D, Braet P, Ahmadi Bidakhvidi N, Deroose CM, et al
(18)F-FDG PET-CT sheds a Light on a Case of Hyponatremia.
J Nucl Med. 2021 Jul 22. pii: jnumed.121.262369. doi: 10.2967/jnumed.121.262369.
PubMed Abstract available

VONKEN EPA, Bruijnen RCG, Snijders TJ, Seute T, et al
Intra-arterial administration boosts (177)Lu-HA-DOTATATE accumulation in salvage meningioma patients.
J Nucl Med. 2021 Jul 22. pii: jnumed.121.262491. doi: 10.2967/jnumed.121.262491.
PubMed Abstract available

ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
PubMed Abstract available

SANCHEZ-CATASUS C, Bohnen NI, D'Cruz N, Muller M, et al
Striatal acetylcholine-dopamine imbalance in Parkinson's disease: in vivo neuroimaging study with dual-tracer PET and dopaminergic PET-informed correlational tractography.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.261939. doi: 10.2967/jnumed.121.261939.
PubMed Abstract available

IMPERIALE A, Boursier C, Sahakian N, Ouvrard E, et al
Values of (68)Ga-DOTATOC and Carbidopa-assisted (18)F-DOPA PET/CT for insulinoma localization.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.262401. doi: 10.2967/jnumed.121.262401.
PubMed Abstract available

THORNTON A, Fraioli F, Wan S, Garthwaite HS, et al
Evolution of (18)F-FDG-PET/CT findings in patients following COVID-19 pneumonia: An Initial Investigation.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.262296. doi: 10.2967/jnumed.121.262296.
PubMed Abstract available

BENZ MR, Armstrong WR, Ceci F, Polverari G, et al
(18)F-FDG PET/CT imaging biomarkers for early and late evaluation of response to first-line chemotherapy in patients with pancreatic ductal adenocarcinoma.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.261952. doi: 10.2967/jnumed.121.261952.
PubMed Abstract available

NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
PubMed Abstract available

READER AJ, Schramm G
AI for PET image reconstruction.
J Nucl Med. 2021 Jul 8. pii: jnumed.121.262303. doi: 10.2967/jnumed.121.262303.
PubMed

IM C, Kim H, Zaheer J, Kim JY, et al
PET tracing of biodistribution for orally administered (64)Cu-labeled polystyrene in mice.
J Nucl Med. 2021 Jul 2. pii: jnumed.120.256982. doi: 10.2967/jnumed.120.256982.
PubMed Abstract available

BOSS M, Rottenburger C, Brenner W, Blankenstein O, et al
(68)Ga-NODAGA-exendin-4 PET improves the detection of focal congenital hyperinsulinism.
J Nucl Med. 2021 Jul 2. pii: jnumed.121.262327. doi: 10.2967/jnumed.121.262327.
PubMed Abstract available

CERCI JJ, Fanti S, Lobato EE, Kunikowska J, et al
Diagnostic performance and clinical impact of (68)Ga-PSMA-11 imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study).
J Nucl Med. 2021 Jul 2. pii: jnumed.120.261886. doi: 10.2967/jnumed.120.261886.
PubMed Abstract available

STATES LJ, Davis JC, Hamel SM, Becker SA, et al
(18)F-6-Fluoro-l-Dopa PET/CT Imaging of Congenital Hyperinsulinism.
J Nucl Med. 2021;62.
PubMed Abstract available

WAHL R
Nuclear Medicine Innovations: Providing Access for All.
J Nucl Med. 2021;62:16N.
PubMed

MARZELLA L, Czernin J, Hope T
Perspectives on Radiopharmaceutical Agents from the FDA: A Conversation between Lou Marzella, Johannes Czernin, and Thomas Hope.
J Nucl Med. 2021;62:881-883.
PubMed

BLAZHENETS G, Schroeter N, Bormann T, Thurow J, et al
Slow but Evident Recovery from Neocortical Dysfunction and Cognitive Impairment in a Series of Chronic COVID-19 Patients.
J Nucl Med. 2021;62:910-915.
PubMed Abstract available

WILD D, Antwi K, Fani M, Christ ER, et al
Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
J Nucl Med. 2021;62.
PubMed Abstract available

HINDIE E, Schwartz P, Avram AM, Imperiale A, et al
Primary Hyperparathyroidism: Defining the Appropriate Preoperative Imaging Algorithm.
J Nucl Med. 2021;62.
PubMed Abstract available

CRANDALL JP, Wahl RL
Perspectives on Brown Adipose Tissue Imaging: Insights from Preclinical and Clinical Observations from the Last and Current Century.
J Nucl Med. 2021;62.
PubMed Abstract available

SUNDIN A, Hindie E, Avram AM, Tabarin A, et al
A Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses.
J Nucl Med. 2021;62.
PubMed Abstract available

June 2021

BARCA C, Kiliaan AJ, Foray C, Wachsmuth L, et al
A longitudinal PET/MR imaging study of colony stimulating factor-1 receptor-mediated microglia depletion in experimental stroke.
J Nucl Med. 2021 Jun 24. pii: jnumed.121.262279. doi: 10.2967/jnumed.121.262279.
PubMed Abstract available

CZERNIN J, Calais J
(177)Lu-PSMA617 and the VISION Trial: One of the Greatest Success Stories in the History of Nuclear Medicine.
J Nucl Med. 2021 Jun 24. pii: jnumed.121.262710. doi: 10.2967/jnumed.121.262710.
PubMed

MEIER SR, Sehlin D, Roshanbin S, Lim Falk V, et al
(11)C-PIB and (124)I-antibody PET provide differing estimates of brain amyloid-beta after therapeutic intervention.
J Nucl Med. 2021 Jun 4. pii: jnumed.121.262083. doi: 10.2967/jnumed.121.262083.
PubMed Abstract available

WAKFIE-CORIEH CG, Ferrando-Castagnetto F, Blanes Garcia AM, Garcia-Esquinas MG, et al
Incidental findings suggestive of COVID-19 pneumonia in oncological patients undergoing 18F-FDG PET/CT studies: association between metabolic and structural lung changes.
J Nucl Med. 2021 Jun 4. pii: jnumed.121.261915. doi: 10.2967/jnumed.121.261915.
PubMed Abstract available

ZHANG X, Landgraf L, Bailis N, Unger M, et al
Image-guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
J Nucl Med. 2021 Jun 4. pii: jnumed.120.256230. doi: 10.2967/jnumed.120.256230.
PubMed Abstract available

DASHORA HR, Rosenblum JS, Quinn KA, Alessi H, et al
Comparing Semi-quantitative and Qualitative Methods of Vascular FDG-PET Activity Measurement in Large-Vessel Vasculitis.
J Nucl Med. 2021 Jun 4. pii: jnumed.121.262326. doi: 10.2967/jnumed.121.262326.
PubMed Abstract available

MIX M, Renaud T, Kind F, Nemer U, et al
Kidney doses in (177)Lu-based radioligand therapy in prostate cancer: Is dose estimation based on reduced dosimetry measurements feasible?
J Nucl Med. 2021 Jun 4. pii: jnumed.121.262245. doi: 10.2967/jnumed.121.262245.
PubMed Abstract available

ORELLANA P, Mut F, Estrada E, Lette MM, et al
Status of Nuclear Medicine in Latin America and the Caribbean: IAEA Analysis of Development in the Past 6 Years.
J Nucl Med. 2021;62:23N-29N.
PubMed

ALLIS J, Mankoff D
Industry Perspective on the Changing Nuclear Medicine Landscape: A Conversation Between Jonathan Allis and David Mankoff.
J Nucl Med. 2021;62:749-751.
PubMed

GAN HK, Burge M, Solomon B, Lee ST, et al
A Phase 1 and Biodistribution Study of ABT-806i, an (111)In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806.
J Nucl Med. 2021;62:787-794.
PubMed Abstract available

EBBERS SC, Barentsz MW, de Keizer B, Krijger GC, et al
A Rapid and Safe Infusion Protocol for (177)Lu Peptide Receptor Radionuclide Therapy.
J Nucl Med. 2021;62:816-822.
PubMed Abstract available

ERIKSSON O, Velikyan I, Haack T, Bossart M, et al
Imaging of the Glucagon Receptor in Subjects with Type 2 Diabetes.
J Nucl Med. 2021;62:833-838.
PubMed Abstract available

May 2021

GAFITA A, Wang H, Robertson A, Armstrong WR, et al
Tumor sink effect in (68)Ga-PSMA-11 PET: Myth or Reality?
J Nucl Med. 2021 May 28. pii: jnumed.121.261906. doi: 10.2967/jnumed.121.261906.
PubMed Abstract available

RAMAN F, Fang YD, Grandhi S, Murchison CF, et al
Dynamic Amyloid PET: Relationships to Flortaucipir Tau PET Measures.
J Nucl Med. 2021 May 28. pii: jnumed.120.254490. doi: 10.2967/jnumed.120.254490.
PubMed Abstract available

JIN X, Wei M, Wang S, Wang G, et al
Detecting fibroblast activation proteins in lymphoma using (68)Ga-FAPI PET/CT.
J Nucl Med. 2021 May 28. pii: jnumed.121.262134. doi: 10.2967/jnumed.121.262134.
PubMed Abstract available

JACENE HA, Liu M, Cheng SC, Abbott A, et al
Imaging Androgen Receptors in Breast Cancer with (18)F-fluoro-5alpha-dihydrotestosterone-PET: A Pilot Study.
J Nucl Med. 2021 May 28. pii: jnumed.121.262068. doi: 10.2967/jnumed.121.262068.
PubMed Abstract available

SEBAN RD, Champion L, Muneer I, Synn S, et al
Potential theranostic role of bone marrow glucose metabolism on baseline [18F]-FDG PET/CT in metastatic melanoma.
J Nucl Med. 2021 May 28. pii: jnumed.121.262361. doi: 10.2967/jnumed.121.262361.
PubMed

KRAUS S, Dierks A, Rasche L, Kertels O, et al
(68)Ga-Pentixafor-PET/CT imaging represents a novel approach to detect chemokine receptor CXCR4 expression in myeloproliferative neoplasms.
J Nucl Med. 2021 May 28. pii: jnumed.121.262206. doi: 10.2967/jnumed.121.262206.
PubMed Abstract available

MUNOZ C, Ellis S, Nekolla SG, Kunze KP, et al
MR-guided motion-corrected PET image reconstruction for cardiac PET-MR.
J Nucl Med. 2021 May 28. pii: jnumed.120.254235. doi: 10.2967/jnumed.120.254235.
PubMed Abstract available

NICKOLS N, Anand A, Johnsson K, Brynolfsson J, et al
aPROMISE: A Novel Automated-PROMISE platform to Standardize Evaluation of Tumor Burden in (18)F-DCFPyL (PSMA) images of Veterans with Prostate Cancer.
J Nucl Med. 2021 May 28. pii: jnumed.120.261863. doi: 10.2967/jnumed.120.261863.
PubMed Abstract available

BIECHELE G, Sebastian Monasor L, Wind K, Blume T, et al
Glitter in the Darkness? Non-fibrillar beta-amyloid Plaque Components Significantly Impact the beta-amyloid PET Signal in Mouse Models of Alzheimer's Disease.
J Nucl Med. 2021 May 20. pii: jnumed.120.261858. doi: 10.2967/jnumed.120.261858.
PubMed Abstract available

ZARAGORI T, Oster J, Roch V, Hossu G, et al
(18)F-FDOPA PET for the non-invasive prediction of glioma molecular parameters: a radiomics study.
J Nucl Med. 2021 May 20. pii: jnumed.120.261545. doi: 10.2967/jnumed.120.261545.
PubMed Abstract available

GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
PubMed Abstract available

MORAWITZ J, Bruckmann NM, Dietzel F, Ullrich T, et al
Determining the axillary nodal status with four current imaging modalities including (18)F-FDG PET/MRI in newly diagnosed breast cancer: A comparative study using histopathology as reference standard.
J Nucl Med. 2021 May 20. pii: jnumed.121.262009. doi: 10.2967/jnumed.121.262009.
PubMed Abstract available

COLLET S, Guillamo JS, Berro DH, Chakhoyan A, et al
Simultaneous mapping of vasculature, hypoxia and proliferation using DSC-MRI, (18)F-FMISO PET, and (18)F-FLT PET in relation to contrast enhancement in newly diagnosed glioblastoma.
J Nucl Med. 2021 May 20. pii: jnumed.120.249524. doi: 10.2967/jnumed.120.249524.
PubMed Abstract available

BARBATO F, Fendler WP, Rauscher I, Herrmann K, et al
PSMA-PET for the assessment of metastatic hormone-sensitive prostate cancer volume of disease.
J Nucl Med. 2021 May 14. pii: jnumed.121.262120. doi: 10.2967/jnumed.121.262120.
PubMed Abstract available

EL-ATOUM B, Ebert M, Bucher B, Afify Z, et al
Is (18)F-FDG PET/CT effective in identifying true residual disease after treatment of pediatric PTLD?
J Nucl Med. 2021 May 14. pii: jnumed.121.262414. doi: 10.2967/jnumed.121.262414.
PubMed

BOERS J, Loudini N, Brunsch CL, Koza SA, et al
Value of (18)F-FES-PET to solve clinical dilemmas in breast cancer patients: a retrospective study.
J Nucl Med. 2021 May 14. pii: jnumed.120.256826. doi: 10.2967/jnumed.120.256826.
PubMed Abstract available

HENDERSON TA, DeBruin S, Briandet P
(18)F-FDG PET National Coverage Determination for Infection/Inflammation Retired.
J Nucl Med. 2021;62:18N-22N.
PubMed

WAHL RL, Ahuja S, Clarke B
Current Landscape of Radiopharmaceutical Therapies: SNMMI Therapy Task Force Survey.
J Nucl Med. 2021;62:11N-16N.
PubMed

Challenges and Promise for Nuclear Medicine in Africa: A Conversation Between Mike Sathekge and Johannes Czernin.
J Nucl Med. 2021;62:593-595.
PubMed

YOSHINAGA K, Abe T, Okamoto S, Uchiyama Y, et al
Effects of Repeated (131)I-Meta-Iodobenzylguanidine Radiotherapy on Tumor Size and Tumor Metabolic Activity in Patients with Metastatic Neuroendocrine Tumors.
J Nucl Med. 2021;62:685-694.
PubMed Abstract available

NAZERI A, Crandall JP, Fraum TJ, Wahl RL, et al
Repeatability of Radiomic Features of Brown Adipose Tissue.
J Nucl Med. 2021;62:700-706.
PubMed Abstract available

FENG T, Zhao Y, Shi H, Li H, et al
Total-Body Quantitative Parametric Imaging of Early Kinetics of (18)F-FDG.
J Nucl Med. 2021;62:738-744.
PubMed Abstract available

SCHAEFER WM, Knollmann D, Meyer PT
Q/V-SPECT CT in times of COVID-19: Changing the order to improve safety without sacrificing accuracy.
J Nucl Med. 2021 May 7. pii: jnumed.120.261263. doi: 10.2967/jnumed.120.261263.
PubMed

April 2021

KESSLER L, Ferdinandus J, Hirmas N, Bauer S, et al
Ga-68-FAPI as diagnostic tool in sarcoma: Data from the FAPI-PET prospective observational trial.
J Nucl Med. 2021 Apr 30. pii: jnumed.121.262096. doi: 10.2967/jnumed.121.262096.
PubMed Abstract available

COHEN AS, Grudzinski J, Smith GT, Peterson TE, et al
First-in-human PET imaging and estimated radiation dosimetry of L-[5-(11)C]-glutamine in patients with metastatic colorectal cancer.
J Nucl Med. 2021 Apr 30. pii: jnumed.120.261594. doi: 10.2967/jnumed.120.261594.
PubMed Abstract available

CHENG JL, Dibble EH, Baird GL, Gordon LL, et al
Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors.
J Nucl Med. 2021 Apr 23. pii: jnumed.120.260711. doi: 10.2967/jnumed.120.260711.
PubMed Abstract available

KWIECINSKI J, Tzolos E, Meah M, Cadet S, et al
Machine-learning with (18)F-sodium fluoride PET and quantitative plaque analysis on CT angiography for the future risk of myocardial infarction.
J Nucl Med. 2021 Apr 23. pii: jnumed.121.262283. doi: 10.2967/jnumed.121.262283.
PubMed Abstract available

FENDLER WP, Herrmann K, Eiber M
Nuclear Medicine beyond VISION.
J Nucl Med. 2021 Apr 23. pii: jnumed.121.262441. doi: 10.2967/jnumed.121.262441.
PubMed

CHEN R, Wang Y, Zhu Y, Shi Y, et al
The added value of (18)F-FDG PET/CT compared to (68)Ga-PSMA PET/CT in patients with castration-resistant prostate cancer.
J Nucl Med. 2021 Apr 23. pii: jnumed.121.262250. doi: 10.2967/jnumed.121.262250.
PubMed Abstract available

EIFER M, Tau N, Alhoubani Y, Kanana N, et al
Covid-19 mRNA Vaccination: Age and Immune Status and its Association with Axillary Lymph Node PET/CT Uptake.
J Nucl Med. 2021 Apr 23. pii: jnumed.121.262194. doi: 10.2967/jnumed.121.262194.
PubMed Abstract available

GHZALLY Y, Imanli H, Smith M, Mahat J, et al
Metabolic Scar Assessment with (18)F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites.
J Nucl Med. 2021 Apr 23. pii: jnumed.120.246413. doi: 10.2967/jnumed.120.246413.
PubMed Abstract available

GOGOLA A, Minhas DS, Villemagne VL, Cohen AD, et al
Direct comparison of the tau PET tracers [(18)F]flortaucipir and [(18)F]MK-6240 in human subjects.
J Nucl Med. 2021 Apr 16. pii: jnumed.120.254961. doi: 10.2967/jnumed.120.254961.
PubMed Abstract available

YOUNG AJ, Pantel AR, Viswanath V, Dominguez TL, et al
Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted (18)F-FluorThanatrace ((18)F-FTT) PET images of ovarian cancer.
J Nucl Med. 2021 Apr 16. pii: jnumed.121.261894. doi: 10.2967/jnumed.121.261894.
PubMed Abstract available

QIN C, Shao F, Gai Y, Liu Q, et al
(68)Ga-DOTA-FAPI-04 PET/MR in the evaluation of gastric carcinomas: comparison with (18)F-FDG PET/CT.
J Nucl Med. 2021 Apr 16. pii: jnumed.120.258467. doi: 10.2967/jnumed.120.258467.
PubMed Abstract available

LUKEY PT, Wilson FJ
Quantification of the alphavbeta6 Integrin by PET/CT Imaging in the Lungs of Patients after SARS-CoV2 Infection and Comparison to Fibrotic Lungs.
J Nucl Med. 2021 Apr 9. pii: jnumed.121.262342. doi: 10.2967/jnumed.121.262342.
PubMed

GUGLIELMETTI C, Levi J, Huynh TL, Tiret B, et al
Longitudinal imaging of T-cells and inflammatory demyelination in a preclinical model of multiple sclerosis using (18)F-FAraG PET and MRI.
J Nucl Med. 2021 Apr 9. pii: jnumed.120.259325. doi: 10.2967/jnumed.120.259325.
PubMed Abstract available

KUO HT, Lin KS, Zhang Z, Uribe CF, et al
(177)Lu-Labeled Albumin-Binder-Conjugated PSMA-Targeting Agents with Extremely High Tumor Uptake and Enhanced Tumor-to-Kidney Absorbed Dose Ratio.
J Nucl Med. 2021;62:521-527.
PubMed Abstract available

March 2021

ALSULTAN AA, van Roekel C, Barentsz MW, Smits MLJ, et al
Dose-response and dose-toxicity relationships for yttrium-90 glass radioembolization in patients with colorectal cancer liver metastases.
J Nucl Med. 2021 Mar 19. pii: jnumed.120.255745. doi: 10.2967/jnumed.120.255745.
PubMed Abstract available

WU H, Czernin J
A Conversation Between Hong Wu and Johannes Czernin.
J Nucl Med. 2021;62:293-295.
PubMed

LODGE MA
Phantom Preparation Using a Dilution Technique.
J Nucl Med. 2021;62:303.
PubMed

ALBRECHT J, Exner S, Grotzinger C, Prasad S, et al
Multimodal Imaging of 2-Cycle PRRT with (177)Lu-DOTA-JR11 and (177)Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.
J Nucl Med. 2021;62:393-398.
PubMed Abstract available

BARRINGTON SF, Zwezerijnen BGJC, de Vet HCW, Heymans MW, et al
Automated Segmentation of Baseline Metabolic Total Tumor Burden in Diffuse Large B-Cell Lymphoma: Which Method Is Most Successful? A Study on Behalf of the PETRA Consortium.
J Nucl Med. 2021;62:332-337.
PubMed Abstract available

PEREIRA PMR, Norfleet J, Lewis JS, Escorcia FE, et al
Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition.
J Nucl Med. 2021;62:366-371.
PubMed Abstract available

February 2021

SUH M, Im HJ, Ryoo HG, Kang KW, et al
Head to head comparison of (68)Ga-NGUL and (68)Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study.
J Nucl Med. 2021 Feb 26. pii: jnumed.120.258434. doi: 10.2967/jnumed.120.258434.
PubMed Abstract available

SARTOR O, Hope TA, Calais J, Fendler WP, et al
Oliver Sartor Talks with Thomas A. Hope, Jeremie Calais, and Wolfgang P. Fendler About FDA Approval of PSMA.
J Nucl Med. 2021;62:146-148.
PubMed

CARLUCCI G, Ippisch R, Slavik R, Mishoe A, et al
(68)Ga-PSMA-11 NDA Approval: A Novel and Successful Academic Partnership.
J Nucl Med. 2021;62:149-155.
PubMed Abstract available

ZANOTTI-FREGONARA P, Lammertsma AA, Innis RB
(11)C Dosimetry Scans Should Be Abandoned.
J Nucl Med. 2021;62:158-159.
PubMed

ALTMANN A, Haberkorn U, Siveke J
The Latest Developments in Imaging of Fibroblast Activation Protein.
J Nucl Med. 2021;62:160-167.
PubMed Abstract available

SLOMKA PJ, Moody JB, Miller RJH, Renaud JM, et al
Quantitative clinical nuclear cardiology, part 2: Evolving/emerging applications.
J Nucl Med. 2021;62:168-176.
PubMed Abstract available

AHMED H, Wallimann R, Haider A, Hosseini V, et al
Preclinical Development of (18)F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis.
J Nucl Med. 2021;62:259-265.
PubMed Abstract available

HADDAD J, Latoche JD, Nigam S, Bellavia MC, et al
Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
J Nucl Med. 2021;62:280-286.
PubMed Abstract available

January 2021

ARMSTRONG WR, Gafita A, Zhu S, Thin P, et al
The impact of monosodium glutamate on (68)Ga-PSMA-11 biodistribution in men with prostate cancer: a prospective randomized, controlled, imaging study.
J Nucl Med. 2021 Jan 28. pii: jnumed.120.257931. doi: 10.2967/jnumed.120.257931.
PubMed Abstract available

BODAR YJL, Koene BPF, Jansen BHE, Cysouw MCF, et al
Standardized Uptake Values are Adequate Measures of Lesional (18)F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden.
J Nucl Med. 2021 Jan 28. pii: jnumed.120.260232. doi: 10.2967/jnumed.120.260232.
PubMed Abstract available

LAFFON E, Marthan R
Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
J Nucl Med. 2021;62:144.
PubMed

BUVAT I, Herrmann K, Stremitzer A, Tobia K, et al
Irene Buvat and Ken Herrmann Talk with Alexander Stremitzer, Kevin Tobia, and Aileen Nielsen.
J Nucl Med. 2021;62:3-5.
PubMed

PRICE WN 2ND, Gerke S, Cohen IG
How Much Can Potential Jurors Tell Us About Liability for Medical Artificial Intelligence?
J Nucl Med. 2021;62:15-16.
PubMed

TOBIA K, Nielsen A, Stremitzer A
When Does Physician Use of AI Increase Liability?
J Nucl Med. 2021;62:17-21.
PubMed Abstract available

CAPOBIANCO N, Meignan M, Cottereau AS, Vercellino L, et al
Deep-Learning (18)F-FDG Uptake Classification Enables Total Metabolic Tumor Volume Estimation in Diffuse Large B-Cell Lymphoma.
J Nucl Med. 2021;62:30-36.
PubMed Abstract available

ZIESSMAN HA, Jeyasingam M, Khan AU, McMahan Z, et al
Experience with Esophagogastrointestinal Transit Scintigraphy in the Initial 229 Patients: Multiple Regions of Dysmotility Are Common.
J Nucl Med. 2021;62:115-122.
PubMed Abstract available

November 2020

AYATI N, Lee ST, Zakavi SR, Cheng M, et al
Response evaluation and survival prediction following PD-1 immunotherapy in patients with non-small-cell lung cancer: comparison of assessment methods.
J Nucl Med. 2020 Nov 27. pii: jnumed.120.254508. doi: 10.2967/jnumed.120.254508.
PubMed Abstract available

October 2020

VIDAL-SICART S, Rioja ME, Prieto A, Goni E, et al
Sentinel Lymph Node Biopsy in breast cancer with (99m)Tc-Tilmanocept: A novel tracer in the real life. A multicenter study.
J Nucl Med. 2020 Oct 9. pii: jnumed.120.252064. doi: 10.2967/jnumed.120.252064.
PubMed Abstract available

August 2020

MACASKILL MG, Stadulyte A, Williams L, Morgan TEF, et al
Quantification of macrophage-driven inflammation during myocardial infarction with (18)F-LW223, a novel TSPO radiotracer with binding independent of the rs6971 human polymorphism.
J Nucl Med. 2020 Aug 28. pii: jnumed.120.243600. doi: 10.2967/jnumed.120.243600.
PubMed Abstract available

KUMAR M, Salem K, Jeffery JJ, Yan Y, et al
Longitudinal molecular imaging of progesterone receptor reveals early differential response to endocrine therapy in breast cancer with an activating ESR1 mutation.
J Nucl Med. 2020 Aug 28. pii: jnumed.120.249508. doi: 10.2967/jnumed.120.249508.
PubMed Abstract available

NICOLAY NH, Ruhle A, Wiedenmann N, Niedermann G, et al
Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer - Results from a Prospective Imaging Trial.
J Nucl Med. 2020 Aug 28. pii: jnumed.120.248633. doi: 10.2967/jnumed.120.248633.
PubMed Abstract available

BRAGINA O, von Witting E, Garousi J, Zelchan R, et al
Phase I study of (99m)Tc-ADAPT6, a scaffold protein-based probe for visualization of HER2 expression in breast cancer.
J Nucl Med. 2020 Aug 17. pii: jnumed.120.248799. doi: 10.2967/jnumed.120.248799.
PubMed Abstract available

June 2020

VAN ROEKEL C, Bastiaannet R, Smits MLJ, Bruijnen RC, et al
Dose-effect relationships of holmium-166 radioembolization in colorectal cancer.
J Nucl Med. 2020 Jun 26. pii: jnumed.120.243832. doi: 10.2967/jnumed.120.243832.
PubMed Abstract available

May 2020

HARSINI S, Saprunoff H, Alden TM, Mohammadi B, et al
The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intra-individual imaging study.
J Nucl Med. 2020 May 8. pii: jnumed.120.246983. doi: 10.2967/jnumed.120.246983.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Nuclear Medicine is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: